Good Practices in the Conduct of Clinical Trials: Good Community, Pharmacy and Laboratory Practices
Abstract
In addition to essential Good Clinical Practice (GCP) and Human Subject Protection (HSP) training that all study staff implementing clinical trials receive, CAPRISA has several science support cores to further enhance the quality of clinical trial conduct. This chapter shares experiences and insights from the Pharmacy, Laboratory and Community Cores that have been garnered over several decades of conducting clinical trials and provides insights on the systems for ensuring scientific integrity and meeting ethical obligations. Experiences on establishing respectful partnerships with communities where the research is being undertaken and preparing volunteers for informed and voluntary study participation are highlighted as well as good pharmacy and laboratory practices. The Pharmacy core has to ensure blinding, integrity of the investigational new drug, correct and accurate dispensing of study product to participants and accountability for products dispensed. The Laboratory core needs to ensure that systems are in place for correct specimen collection; the best and most appropriate laboratory assays are utilised, the specimens are transported appropriately and processing for storage or further shipping is accurate. Given that not all assays are performed in real time, the Laboratory Core has to maintain an effective and efficient specimen repository/BioBank to locate and ship specimens to local and international collaborating laboratories. These three science support cores have been set up to function across multiple clinical trials in different geographical locations ensuring cost-effectiveness and efficiency.
Keywords
Community Advisory board Good practices Research pharmacy Research laboratory Process optimisation Standard operating proceduresReferences
- 1.The South African Pharmacy Council. Good Pharmacy Practice Manual. Fourth ed; 2010.Google Scholar
- 2.Pharmacy Act (Act 53 of 1974), Regulations and Rules (Ethical Rule 4).Google Scholar
- 3.Republic of South Africa. Medicines and Related Substances Control Act (Act 101 of 1965) and General Regulations (section 22A, Regulation 34, 35). Available at http://www.mccza.com/Publications/DownloadDoc/44 (accessed 30 January 2016).
- 4.International conference on harmonisation, Guidileine for Good Clinical Practice. Retrieved 12 January 2016 from http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html.
- 5.South African Department of Health. Guidelines for Good Practice in the Conduct of Clinical Trials in Human Participants in South Africa. 2006. Google Scholar
- 6.Frohlich J, Kirkendale SS, Wilson WL, Abdool Karima Q, Morin SF, Wakefield S. Establishing community involvement in an international HIV prevention research network: Issues and challenges. July 7-12; 14: abstract no. MoPeG4170. 1. Int Conf AIDS; 2002; 2002. Google Scholar
- 7.Swartz L, Kagee A. Community participation in AIDS vaccine trials: empowerment or science? Soc Sci Med 2006; 63(5): 1143–6. Google Scholar
- 8.Campbell C, Nair Y, Maimane S. Building contexts that support effective community responses to HIV/AIDS: a South African case study. Am J Community Psychol 2007; 39(3-4): 347–63.Google Scholar
- 9.Tindana PO, Singh JA, Tracy CS, Upshur REG, Daar AS, Singer PA, et al. Grand challenges in global health: community engagement in research in developing countries. PLoS Med 2007; 4(9): e273.Google Scholar
- 10.UNAIDS. Good Participatory Practice. Guidelines for biomedical HIV prevention trials. 2011.Google Scholar
- 11.Robinson ET, Baron D, Heise LL, Moffett J, Harlan SV. Communications Handbook for Clinical Trials. Family Health International.; 2010.Google Scholar